Literature DB >> 2903308

Embryopathy in infant conceived one year after termination of maternal etretinate.

E J Lammer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2903308     DOI： 10.1016/s0140-6736(88)90101-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Persistent etretinate levels in plasma after changing the therapy to acitretin.

Authors:  W E Lambert; A P De Leenheer; J P De Bersaques; A Kint
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Risk classification systems for drug use during pregnancy: are they a reliable source of information?

Authors:  A Addis; S Sharabi; M Bonati
Journal:  Drug Saf       Date:  2000-09       Impact factor: 5.606

3.  Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment.

Authors:  M C Sturkenboom; L T de Jong-Van Den Berg; P C van Voorst-Vader; M C Cornel; B H Stricker; H Wesseling
Journal:  Br J Clin Pharmacol       Date:  1994-09       Impact factor: 4.335

4.  Vitamin A--a pregnancy hazard alert.

Authors:  K W Kizer; A M Fan; J Bankowska; R J Jackson; D O Lyman
Journal:  West J Med       Date:  1990-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.